EPIX - Epix Pharmaceuticals Inc

Check it out. They have lots coming out and due to very low volume im guessing have be falling. Beautiful hold on this stock.
I called this stock at $2.89

I Guess I was Totaly right about this stock (it's about another 10% after market. BEAUTIFUL GAPPER FOR TOMORROW)

Press Release Source: Predix Pharmaceuticals


Predix Announces Preliminary Results from Phase Ib Trial of PRX-08066 in Hypoxia-Induced Pulmonary Hypertension
Wednesday April 19, 9:17 am ET
Predix Expects to Initiate Phase IIa Trial of PRX-08066 in Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disorder in Second Half of 2006


LEXINGTON, Mass.--(BUSINESS WIRE)--April 19, 2006--Predix Pharmaceuticals, which recently announced a definitive agreement to merge with EPIX Pharmaceuticals (NASDAQ: EPIX - News), today announced that it has completed a Phase Ib clinical trial to study the pharmacodynamics and tolerability of PRX-08066 in 15 adults conditioned to exercise at high altitudes, with elevated pulmonary artery pressures induced by low oxygen levels (hypoxia). Preliminary results from this trial indicate that treatment with PRX-08066 resulted in a statistically significant reduction in systolic pulmonary blood pressure during exercise hypoxia.
ADVERTISEMENT

Discovered and designed using its proprietary structure-based drug discovery technology and approach, Predix is developing PRX-08066 to provide both symptomatic improvement -- through selective dilation of diseased pulmonary blood vessels -- and to also slow disease progression -- by inhibiting the thickening of the pulmonary artery vessels. Predix believes PRX-08066 is the first 5-HT2B selective antagonist under development for pulmonary hypertension. The 5-HT2B receptor represents a novel target for the treatment of pulmonary hypertension, as it has been linked to both pulmonary vasoconstriction, as well as the smooth muscle hypertrophy found in pulmonary vessels during pulmonary hypertension of various types. Unlike many commonly used vasodilators, Predix believes that PRX-08066 is selective for pulmonary vessels, showing no effect on systemic blood pressures. PRX-08066 has demonstrated selective pulmonary vasodilation in both acute and chronic animal models of PH, as well as potential disease-modifying effects in in vitro biochemical pathway studies. The preliminary results of the Phase Ib trial indicate that in a human model for PH, PRX-08066 significantly reduces pulmonary artery blood pressure during hypoxic exercise, without affecting systemic blood pressure.

Many patients treated for pulmonary hypertension have relatively low systemic blood pressure and do not tolerate multiple drugs with both systemic and pulmonary vasodilatory effects. Because of the selectivity PRX-08066 has shown for hypoxia-induced PH in preclinical and clinical studies, Predix believes that this 5-HT2B antagonist should lack the systemic blood pressure effects of currently approved therapies for patients with pulmonary hypertension of various types. Predix has completed three Phase I clinical trials of PRX-08066 in healthy volunteers, including this Phase Ib trial in athletes conditioned to exercise at high altitudes with PH that has been induced by breathing a gas with a reduced oxygen level.

Still holding this one as well, suppose to be earnings next week. Not sure how that will go.

it wasn't to bad. Still holding.